Outpatient Treatment of Severe and Enduring Anorexia Nervosa

Anorexia Clinical Trial

Official title:

A Novel Outpatient Treatment for Patients With Severe and Enduring Anorexia Nervosa: Patient Characteristics, Treatment Goals, and Course of Treatment.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05708404
• Other study ID #: PISARAAVO
• Status: Completed
• Start date: May 1, 2017
• Est. completion date: May 31, 2022

Study information

• Verified date: January 2023
• Source: Helsinki University Central Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Approximately 20-30 % of individuals with the eating disorder anorexia nervosa develop an enduring form of the illness. In this study a new treatment for patients with severe and enduring anorexia nervosa was described. The treatment is flexible and aims at enhancing quality of life. The participants consisted of all referrals resulting in an assessment or treatment period at the unit between May 2017 and May 2022. The study was a registry study. Information regarding patient characteristics, treatment goals, and the course of treatment was gathered from medical records.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: May 31, 2022
• Est. primary completion date: May 31, 2022
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion criteria:

• Age = 18 years
• A referral resulting in an assessment or treatment period at the unit for patients with severe and enduring anorexia nervosa at the HUS Helsinki University Hospital between May 2017 and May 2022.

Related Conditions & MeSH terms

• Anorexia
• Anorexia Nervosa

Intervention

Behavioral:
• Outpatient treatment of severe and enduring anorexia nervosa
A novel outpatient treatment of severe and enduring anorexia nervosa, aiming at enhancing quality of life and minimizing harm

Locations

Country	Name	City	State
Finland	HUS Syömishäiriöyksikkö	Helsinki	Pl 282

Sponsors (1)

Lead Sponsor	Collaborator
Helsinki University Central Hospital

Country where clinical trial is conducted

Finland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	How the treatment goals were met	Whether or not the patients' individual treatment goals, defined at the beginning of treatment, had been met, partly met, or not met at the end of treatment.	At the end of treatment, an average of 15.4 months